Trial
NCT01956812
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Gilead Sciences
Collaborators
—
Condition
Metastatic Pancreatic Cancer
Intervention
IMMU-107
Why stopped
The DSMB conducted an interim analysis on overall survival, which showed that the treatment arm did not demonstrate a sufficient improvement in OS vs. placebo.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-08-16